The ZytoLight ® SPEC CCND1/IGH Dual Color Dual Fusion Probe is designed to detect translocation t(11;14)(q13.3;q32.3) frequently found in mantle cell lymphomas. The translocation juxtaposes the CCND1 gene (cyclin D1, a.k.a. PRAD1 and BCL1) next to the IGH (immunoglobulin heavy locus, a.k.a. IGH@) locus and results in constitutive overexpression of CCND1. The translocation t(11;14)(q13.3;q32.3) that involves the CCND1 and IGH gene regions is detected in up to 95% of patients with mantle cell lymphomas (MCL) and are considered to be the genetic hallmark of this subtype of low-grade peripheral B-cell neoplasms. However, the t(11;14) has also been identified in other lymphoproliferative disorders (LPDs), such as B-prolymphocytic leukemia (PLL), and, less frequently, in plasma cell myelomas, B-cell chronic lymphocytic leukemia, and in splenic lymphomas with villous lymphocytes (SLVL). Since the course of MCL is aggressive, and its response to standard chemotherapy is poor, differential diagnosis from other chronic lymphoproliferative disorders via detection of the t(11;14) translocation might be of great clinical importance.
